Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
Abstract
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
Domains
Life Sciences [q-bio]Origin | Files produced by the author(s) |
---|